Allogene Therapeutics Inc (ALLO)

2.09 +0.14 (+7.18%) USD  |  NASDAQ  |  Dec 24, 16:00
More

Allogene Therapeutics Max Drawdown (5Y): 96.21% for Nov. 30, 2024

Max Drawdown (5Y) Chart

View Max Drawdown (5Y) for ALLO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Max Drawdown (5Y) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Max Drawdown Definition

View Max Drawdown Definition
Start Trial

Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.

Read full definition.

Max Drawdown (5Y) Range, Past 5 Years

View Max Drawdown (5Y) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Max Drawdown (5Y) Benchmarks

View Max Drawdown (5Y) Benchmarks
Start Trial
ANI Pharmaceuticals Inc 72.96%
AIM ImmunoTech Inc 99.75%
Perspective Therapeutics Inc 91.70%
Protalix BioTherapeutics Inc 94.38%
Armata Pharmaceuticals Inc 99.88%

Max Drawdown (5Y) Related Metrics

Alpha (5Y) -51.96
Beta (5Y) 0.8273
Annualized Standard Deviation of Monthly Returns (5Y Lookback) 75.84%
Historical Sharpe Ratio (5Y) -0.5394
Historical Sortino (5Y) -1.245
Monthly Value at Risk (VaR) 5% (5Y Lookback) 28.48%